Bai Li-Ping, Yu Jing, Sun Ya-Xin, Wang Jiu-Mei
Department of Pediatric Medicine.
Department of Endocrinology, Affiliated Hongqi Hospital of Mudanjiang Medical University.
Medicine (Baltimore). 2019 Sep;98(39):e17239. doi: 10.1097/MD.0000000000017239.
This study aims to evaluate the efficacy and safety of montelukast for the treatment of patients with pediatric allergic purpura (PAP).
We will retrieve the following electronic databases from inception to the present: MEDILINE, Embase, CENTRAL, CINAHL, AMED, Chinese Biomedical Literature Database, China National Knowledge Infrastructure Database, Wanfang, and VIP database without language limitation. Two authors will carry out study selection, data extraction, and quality evaluation independently. RevMan V5.3 software will be used for statistical software.
This study will summarize high-quality evidence-based medicine to evaluate the efficacy and safety of montelukast for the treatment of PAP.
This study will provide strong evidence to determine whether montelukast is an effective and safety treatment for PAP.
PROSPERO CRD42019145472.
本研究旨在评估孟鲁司特治疗小儿过敏性紫癜（PAP）患者的疗效和安全性。
我们将检索从创建到目前的以下电子数据库：MEDILINE、Embase、CENTRAL、CINAHL、AMED、中国生物医学文献数据库、中国知网数据库、万方数据库和维普数据库，无语言限制。两名作者将独立进行研究筛选、数据提取和质量评估。RevMan V5.3软件将用于统计分析。
本研究将总结高质量的循证医学，以评估孟鲁司特治疗PAP的疗效和安全性。
本研究将提供有力证据，以确定孟鲁司特是否为PAP的有效且安全的治疗方法。
PROSPERO CRD42019145472
